Doxycycline

Catalog No.S5159 Synonyms: Vibramycin, Doxytetracycline, Doxiciclina, Doxycyclinum

For research use only.

Doxycycline (Vibramycin, Doxytetracycline, Doxiciclina, Doxycyclinum) is an antibiotic that is used in the treatment of a number of types of infections caused by bacteria and protozoa. Doxycycline is also a nonspecific matrix metalloproteinase (MMP) inhibitor.

Doxycycline Chemical Structure

CAS No. 564-25-0

Selleck's Doxycycline has been cited by 17 publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description Doxycycline (Vibramycin, Doxytetracycline, Doxiciclina, Doxycyclinum) is an antibiotic that is used in the treatment of a number of types of infections caused by bacteria and protozoa. Doxycycline is also a nonspecific matrix metalloproteinase (MMP) inhibitor.
In vitro

100 ng/mL-5 µg/mL Dox can significantly alter the metabolic profile of the cell, as well as reduce the proliferative rate, though the effect size depends upon the particular cell line used[1]. Doxycycline arrests cells in G1-S phase of the cell cycle in PANC-1 cells and induces the expression of p53 and its downstream target p21. It down-regulates antiapoptotic genes and induces proapoptotic genes. Doxycycline also induces apoptosis through a Fas/Fas-ligand dependent pathway in Jurkat T lymphocytes[2].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Staphylococcus aureus 2 planktonic cells MnS0RoFkfGW{aXPp[IFtKGG|c3H5 M2HmZ|I1KGi{cx?= NFHnUIpD[WO2ZYLpZ4ll[WxiYXP0bZZqfHliYXfhbY5{fCCvZYTobYNqdGyrbj3y[ZNqe3SjboSgV5RieGi7bH;jc4NkfXNiYYXy[ZV{KDJicHzhcot1d26rYzDj[YxteyCjZoTldkAzPCCqcoOgZpkh[2GuZ3HyfUBjcW:oaXztJIRmfmmlZTDt[ZRpd2RuIF3CR|0z|ryPLh?= MljFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl4M{ixNlEoRjJ7NkO4NVIyRC:jPh?=
THP1 M3[4bmZ2dmO2aX;uJIF{e2G7 NGfCdFZU\WynY4Tpeol1gSCrbnTlfEwhemG2aX:gc4YhUUN3MDDmc5IhcHWvYX6gWGhROSClZXzsd{B1dyCLQ{WwJIZweiCSbHHzcY9lcXWvIH\hcINqeGG{dX2sJGlEPTB;Mz6x{txONg>? NGDiOm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe0PFc5OSd-MUm3OFg4QDF:L3G+
K562 NEDJbVJEgXSxdH;4bYNqfHliYYPzZZk> M2DNcFczKGi{cx?= NILLNlVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMPTZ{IHPlcIx{KGGodHXyJFczKGi{czDifUBndG:5IHP5eI9u\XS{eTygTWM2OD1zNd88UU4> NYXQUIc1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0PFI1PzZpPkG5OFgzPDd4PD;hQi=>
K562 NXzpbYJtS3m2b4TvfIlkcXS7IHHzd4F6 MkLQO|IhcHK| M1voTGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGs2PjJiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JIZtd3diY4n0c41mfHK7LDDJR|UxRTF3zszNMi=> M37XV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUK2NVc{Lz5zOUmyOlE4OzxxYU6=
HepG2 NELDTXhEgXSxdH;4bYNqfHliYYPzZZk> NU\Qd4tEPzJiaILz MojOR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2yNO69VS5? NXLP[FlYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0PFI1PzZpPkG5OFgzPDd4PD;hQi=>
HepG2 NIDrNXNEgXSxdH;4bYNqfHliYYPzZZk> MmDsO|IhcHK| MWrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUKw{txONg>? MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTl{NkG3N{c,OTl7Mk[xO|M9N2F-
THP1 Mm\YR5l1d3SxeHnjbZR6KGG|c3H5 MYS3NkBpenN? M1vVS2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHRJWDFiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnetZoF{\WRiZnzve{BkgXSxbXX0dpktKEmFNUC9NlDPxE1w NHH1SW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe0PFc5OSd-MUm3OFg4QDF:L3G+
HepG2 NHzwc3dEgXSxdH;4bYNqfHliYYPzZZk> NYP1UGZWPzJiaILz MonKR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhS0N3ME2yNO69VS5? NF3qTIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe0NVE{OSd-MkG3OFEyOzF:L3G+
HepG2 NH7yWWlEgXSxdH;4bYNqfHliYYPzZZk> MX[3NkBpenN? M{TDVmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEOFNUC9NlDPxE1w MorRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6OEm1OVkoRjJ{OEi5OVU6RC:jPh?=
HepG2 NWnmOZJpS3m2b4TvfIlkcXS7IHHzd4F6 M{e5O|czKGi{cx?= NFfsWG9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCFQ{WwQVIx|ryPLh?= NFfRcXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUi1NlE{Oid-MkG4OVIyOzJ:L3G+
HepG2 M2\WeGN6fG:2b4jpZ4l1gSCjc4PhfS=> NX;jVFE3PzJiaILz NFzQTJZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCFQ{WwQVIx|ryPLh?= Ml3sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVYoRjJ2OUS2NlE3RC:jPh?=
HepG2 MlLzR5l1d3SxeHnjbZR6KGG|c3H5 NUTIe4o3PzJiaILz M3;IVmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEOFNUC9NlDPxE1w NILyfW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe5NVY4PSd-MkW3PVE3PzV:L3G+
HepG2 Mn7rR5l1d3SxeHnjbZR6KGG|c3H5 Mn\tO|IhcHK| NUTqUIk3S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiaX7jeYJifGWmIH\vdkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCFQ{WwQVIx|ryPLh?= M{nYflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkiyNlY4Lz5{NUK4NlI3PzxxYU6=
HepG2 M2LuVmN6fG:2b4jpZ4l1gSCjc4PhfS=> NUnRNWptPzJiaILz NH[zfFZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMjDj[YxteyCvZXHzeZJm\CCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCFQ{WwQVIx|ryPLh?= MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF3NUS2N{c,OjdzNUW0OlM9N2F-
HepG2 MkDkR5l1d3SxeHnjbZR6KGG|c3H5 Mm\CO|IhcHK| MlTsR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFPDOVA:OjEQvF2u M1:2O|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NkW0N|k2Lz5{N{[1OFM6PTxxYU6=
SW1353 NYnZXXJiTnWwY4Tpc44h[XO|YYm= NEWzWY42OCC3TR?= MVvJcohq[mm2aX;uJI9nKEmOLUGtZoV1[S2rbnT1Z4VlKE2PUEGzJJBzd2S3Y4Tpc44hcW5iaIXtZY4hW1dzM{WzJINmdGy|IHH0JFUxKHWP NYrnfnZ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUeyOlczOjdpPkG3NlY4OjJ5PD;hQi=>
K-12 BW25113 MYDCZYN1\XKrY3nkZYwh[XO|YYm= NE\5eFgzPCCqcoO= M17SfGJi[3SncnnjbYRidCCjY4Tpeol1gSCjZ3HpcpN1KHmjZmGg[4Vv\S2mZX\pZ4lmdnRiRYPjbIVzcWOqaXGgZ49tcSCNLUGyJGJYOjVzMUOgZolw\mmubTDhd5Nme3OnZDDhd{Btd2dicnXkeYN1cW:wIH;mJJZq[WKuZTDj[YxteyCjZoTldkAzPCCqcoO= M13H[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7M{C3N|c2Lz5zOUOwO|M4PTxxYU6=
K-12 BW25113 MkHFRoFkfGW{aXPp[IFtKGG|c3H5 MXiyOEBpenN? NYLoVopiSmGldHXybYNq\GGuIHHjeIl3cXS7IHHnZYlve3RiRYPjbIVzcWOqaXGgZ49tcSCNLUGyJGJYOjVzMUOgZolw\mmubTDoZZJjd3KrbnegdGNCOjSQIID0ZYM7QnmjZmGgdIxie22rZDDhd5Nme3OnZDDhd{Btd2dicnXkeYN1cW:wIH;mJJZq[WKuZTDj[YxteyCjZoTldkAzPCCqcoOgdJJmfHKnYYTl[EB4cXSqIEWgeW0hd2ZiSWDUS{Bnd3JiNDDodpM> NF;6[JA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUOwO|M4PSd-MUmzNFc{PzV:L3G+
Neuro2a M13iOGZ2dmO2aX;uJIF{e2G7 MYWxJJVO NFnScJNF\WO{ZXHz[UBqdiB5LVTIR{Bt\X[nbIOgbY4hTGilcket[IVncWOrZX70JI1wfXOnIF7leZJwOmFiY3XscJMh[XRiMTD1UUBjgSCOQz3NV{9ISy2PUzDhcoFtgXOrcx?= NGrXVo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVY2Pyd-Mk[3PFk3PTd:L3G+
vascular endothelial cells NHHFeo1CdnSrYnHjeIVzcWGuIHHzd4F6 MW[yOUB2\y:vbB?= MlHXO|IhcHK| M4L2O2FvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCUaXPr[ZR1e2mjIIDyc5digmWtaXmgd5RzNiCEcnXpcowhcW6oZXP0[YQhcW5iQ1SgdoF1KHC{aX3hdpkheHWubX;uZZJ6KH[jc3P1cIFzKGWwZH;0bIVtcWGuIHPlcIx{KGG|c3Xzd4VlKGG|IHLhZ5RmemmjbDDzbIFx\SClaHHu[4Uh[XRiMkWgeYcwdWxibXXhd5Vz\WRiN{KgbJJ{KHCxc4SgbY5n\WO2aX;uJIJ6KEixZXPod5QhOzN{NUivdIhidGyxaXTpckB{fGGrbnnu[{Bj[XOnZDDmcJVweg>? MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDB6OUO1NEc,OjhyOEmzOVA9N2F-
A673 MVzxTHRUKGG|c3H5 NIWwOGVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?= NFXmSmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-12 M4LNdJFJXFNiYYPzZZk> M3LFRpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?= M2jCcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Hep2 M2LFfGFvfGlvQ3jsZY16\GmjbDDhd5NigQ>? M4fIU|EhfWdxbXy= M4rlNlghcHK| MVzBcpRqNUOqbHHtfYRq[WxiYXP0bZZqfHliYXfhbY5{fCCFaHzhcZllcWFidILhZ4hwdWG2aYOgV4Vzd3[jcjDMS3YuVDJiaX7m[YN1\WRiaX6gTIVxOiClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gd4l7\SCjbnSgcpVu[mW{IH;mJINpdGGveXTpZYwhcW6lbIXzbY9vKGG2IEGgeYcwdWxidILlZZRm\CCjdDC4JIhzeyCyb4P0MYlv\mWldHnvckBidmRiMkSgbJJ{KGyjdHXyJJJmNWmwZnXjeIlv\yCocnXzbEBJ\XB{IHPlcIx{KG2xbn;sZZk> MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OjJ{N{m0PEc,OzJ{Mke5OFg9N2F-
skeletal myoblast cells MnnmR5l1d3SxeHnjbZR6KGG|c3H5 MXXEUmRKQiCFeYTveI95cWOrdImgbY4hXmm2cn:sJFczKGixdYKsJIlvKHKjdDDzb4Vt\XSjbDDtfY9jdGG|dDDj[YxteyxiSVO1NF0yPC52Od88UU4> MoXLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQ{Oy9pPlPoSW1DVDxxYU6=
Assay
Methods Test Index PMID
Western blot AKT / BCL6 / Cyclin E / HDAC2 / HDAC3 / NEMO / TYK2 / RIPK1 ; HSP70 / HSP90 ; pATM / ATM 26142707 23282955
Immunofluorescence E-cadherin / Vimentin 29285218
In vivo Doxycycline successfully reduces tumor growth in vivo (inhibited pancreatic cancer cell growth)[2].

Protocol (from reference)

Cell Research:

[1]

  • Cell lines: U87 astrocytoma cells, lung cancer cell lines H157 and H1437, LNCaP prostate cancer and HeLa cervical cancer cell lines
  • Concentrations: 100 ng/mL, 1 µg/mL
  • Incubation Time: 24, 72, and 96 hours
  • Method:

    Cells are seeded in 6 well plates at 50,000 cells per well and treated with Dox (100 ng/mL, 1 µg/mL, or vehicle control). Cells are counted 24, 72, and 96 hours after plating using a particle counter.

Solubility (25°C)

In vitro

DMSO 88 mg/mL
(198.0 mM)
Ethanol '-1 mg/mL

Chemical Information

Molecular Weight 444.43
Formula

C22H24N2O8

CAS No. 564-25-0
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05111002 Not yet recruiting Drug: Lefamulin|Drug: Doxycycline Mycoplasma Genitalium Infection University of Washington|Nabriva Therapeutics AG November 30 2021 Phase 1|Phase 2
NCT04838717 Not yet recruiting Drug: BPG|Drug: Doxycycline Syphilis Assistance Publique - Hôpitaux de Paris November 2021 Phase 3
NCT04860505 Recruiting Drug: Doxycycline|Drug: Biktarvy Sexually Transmitted Diseases Emory University|Centers for Disease Control and Prevention May 20 2021 Phase 4
NCT04762134 Not yet recruiting Drug: Doxycycline Hyclate Bacterial Sexually Transmitted Diseases Jonathan Troy Grennan|Canadian Institutes of Health Research (CIHR)|British Columbia Centre for Disease Control April 1 2021 Phase 2|Phase 3
NCT04597424 Recruiting Drug: Experimental: doxycycline|Biological: Bexsero® vaccine Unsafe Sex|Risk-Taking ANRS Emerging Infectious Diseases January 19 2021 Phase 3
NCT04686799 Recruiting Drug: Doxycycline Hyclate 20 MG Lateral Epicondylitis|Lateral Epicondylitis Left Elbow|Lateral Epicondylitis Right Elbow|Lateral Epicondylitis Unspecified Elbow|Lateral Epicondylitis (Tennis Elbow) Bilateral Hospital for Special Surgery New York December 3 2020 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Doxycycline | Doxycycline supplier | purchase Doxycycline | Doxycycline cost | Doxycycline manufacturer | order Doxycycline | Doxycycline distributor